Cancers, Vol. 10, Pages 430: Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

Cancers, Vol. 10, Pages 430: Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia

Cancers doi: 10.3390/cancers10110430

Authors: Francesca Musumeci Chiara Greco Giancarlo Grossi Alessio Molinari Silvia Schenone

Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-Abl and Src kinase inhibitor. Further studies have indicated that it is a multitargeted inhibitor that is active on FGFRs, RET, AKT, ERK1/2, KIT, MEKK2 and other kinases. For this reason, the compound has been evaluated on several cancers in which these kinases play important roles, including thyroid, breast, ovary and lung cancer, neuroblastoma, rhabdoid tumours and in myeloproliferative disorders. Ponatinib is also being tested in clinical trials to evaluate its activity in FLT3-ITD acute myelogenous leukemia, head and neck cancers, certain type of lung cancer, gastrointestinal stromal tumours and other malignancies. In this review we report the most recent preclinical and clinical studies on ponatinib in cancers other than CML, with the aim of giving a complete overview of this interesting compound.

https://ift.tt/2yZ6urc